Abstract
Circulating miR-155 play a vital role in hypertension. The aim of the present study was to explore the association of miR-155 with blood pressure and inflammatory markers, and to investigate the predictive value of circulating miR-155 for white coat hypertension (WCH). This cross-sectional study was continuously enrolled 105 subjects and was divided into three groups based on office blood pressure monitoring and 24-h ambulatory blood pressure monitoring (ABPM): normal hypertension, WCH, and hypertension group. Circulating miR-155 was assessed by quantitative real-time polymerase chain reaction (qRT-PCR). Spearman correlation coefficient and area under the ROC curve (AUC) were used. We found miR-155 in hypertension group were significantly higher than those in the WCH and normal hypertension group. The level of miR-155 was positively correlated with C-reactive protein, interleukin-6, office systolic blood pressure (SBP), and diastolic blood pressure (DBP), and ABMP parameters (24-h SBP, 24-h DBP, 24-h daytime SBP, 24-h daytime DBP, 24-h nighttime SBP and 24 h nighttime DBP) (all P < 0.05). Circulating miR-155 yielded an AUC of 0.843 (95% CI: 0.753, 0.933; P < 0.001) and 0.832 (95% CI: 0.736, 0.928; P < 0.001) for differing hypertension and WCH from control subjects, respectively. Our results suggested that miR-155 was significantly associated with inflammatory markers, and may become a potential noninvasive marker for WCH detection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kollias A, Ntineri A, Stergiou GS. Is white-coat hypertension a harbinger of increased risk? Hypertens Res. 2014;37:791–5.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34:2159–219.
Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359–66.
Martin CA, McGrath BP. White-coat hypertension. Clin Exp Pharmacol Physiol. 2014;41:22–9.
Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, et al. Prognosis of white-coat and masked hypertension: International database of home blood pressure in relation to cardiovascular outcome. Hypertension. 2014;63:675–82.
Abolbashari M. White coat hypertension and cardiovascular diseases: innocent or guilty. Curr Cardiol Rep. 2018;20:25.
Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11:252–63.
Synetos A, Toutouzas K, Stathogiannis K, Latsios G, Tsiamis E, Tousoulis D, et al. MicroRNAs in arterial hypertension. Curr Top Med Chem. 2013;13:1527–32.
Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575–84.
Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24:241–6.
DuPont JJ, McCurley A, Davel AP, McCarthy J, Bender SB, Hong K, et al. Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging. JCI Insight. 2016;1:e88942.
Klimczak D, Kuch M, Pilecki T, Zochowska D, Wirkowska A, Paczek L. Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension. J Am Soc Hypertens. 2017;11:831–41.
Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepien E, et al. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn. 2011;121:361–6.
Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79:581–8.
Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960.
Sipahioglu NT, Sipahioglu F. Closer look at white-coat hypertension. World J Method. 2014;4:144–50.
Yavuzer H, Cengiz M, Yavuzer S, Riza AM, Korkmazer B, Balci H, et al. Procalcitonin and pentraxin-3: current biomarkers in inflammation in white coat hypertension. J Hum Hypertens. 2016;30:424–9.
Huang YQ, Huang C, Chen JY, Li J, Feng YQ. The association of circulating miR-30a, miR-29 and miR-133 with white-coat hypertension. Biomark Med. 2016;10:1231–9.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.
Kang K, Zhang X, Liu H, Wang Z, Zhong J, Huang Z, et al. A novel real-time PCR assay of microRNAs using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent sensitivity and specificity. PLoS One. 2012;7:e48536.
Baraniskin A, Nopel-Dunnebacke S, Ahrens M, Jensen SG, Zollner H, Maghnouj A, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013;132:E48–E57.
Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101:530–5.
Cengiz M, Karatas OF, Koparir E, Yavuzer S, Ali C, Yavuzer H, et al. Differential expression of hypertension-associated microRNAs in the plasma of patients with white coat hypertension. Medicine. 2015;94:e693.
Sinha N, Dabla PK. Oxidative stress and antioxidants in hypertension-a current review. Curr Hypertens Rev. 2015;11:132–42.
Ozdogan M, Bozcuk H, Coban E. Low-grade inflammation in white-coat hypertension. Med Sci Monit. 2007;13:R570–3.
Andrikou I, Tsioufis C, Dimitriadis K, Syrseloudis D, Valenti P, Almiroudi M, et al. Similar levels of low-grade inflammation and arterial stiffness in masked and white-coat hypertension: comparisons with sustained hypertension and normotension. Blood Press Monit. 2011;16:218–23.
Huang Y, Chen J, Zhou Y, Tang S, Li J, Yu X, et al. Circulating miR155 expression level is positive with blood pressure parameters: Potential markers of target-organ damage. Clin Exp Hypertens. 2016;38:331–6.
Simoes ESA, Flynn JT. The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol. 2012;27:1835–45.
Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60:1407–14.
Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens. 2015;33:1128–36.
O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007;104:1604–9.
Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost. 2012;107:611–8.
Acknowledgements
This work was supported by the Natural Science Foundation of Guangdong Province (No. 2015A030313660), the Science and Technology Plan Project of Guangdong Province (No. 2014B020212008), the Science and Technology Program of Guangzhou (No. 201604020143, No. 201604020018, No. 201604020186, No. 201510010254, and No. 201803040012), and the National Key Research and Development Program of China (No. 2017YFC1307603, No. 2016YFC1301305, and No. 2017YFC0909303), the Key Area R&D Program of Guangdong Province (No. 2019B020227005).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Huang, Yq., Huang, C., Zhang, B. et al. Association of circulating miR-155 expression level and inflammatory markers with white coat hypertension. J Hum Hypertens 34, 397–403 (2020). https://doi.org/10.1038/s41371-019-0250-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-019-0250-7